Track topics on Twitter Track topics that are important to you
Oxford Gene Technology Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m
Oxford and Cambridge, UK – 2 December 2014 – Following its successful acquisition and integration of Cytocell Ltd, Oxford Gene Technology (OGT), the molecular genetics company, has provided an operational and financial update for the company’s financial year ended 30 September 2014.
Commenting on OGT’s performance and the outlook for 2015, Dr Mike Evans, CEO of OGT said:
“We have made some important operational decisions this year to help achieve our ambition to become a global leader in molecular genetics.
“A key component to our growth was the acquisition of Cytocell. As well as being financially accretive to the business, it has expanded the portfolio of products available to our dedicated sales force, allowing us to offer our customers the complete solution for molecular genetics research.
“Our R&D team has made significant progress on a number of high-value projects addressing the escalating NIPT and NGS markets, which will further fuel OGT’s growth.
“We now have an international infrastructure supporting sales in over 60 countries, a focused portfolio and strong development pipeline to take advantage of the continued high growth of the molecular genetics market. We expect to see continued momentum in the next financial year and beyond, building further value to our customers and the business.”Oxford Gene Technology Stephen Archibald, Director of Communications T: +44 (0) 1865 856826 F: +44 (0) 1865 848684 E: firstname.lastname@example.org NEXT ARTICLE
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...